Research analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.
Separately, Ascendiant Capital Markets lowered their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.
Get Our Latest Report on NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Price Performance
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Recommended Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Top 3 Investment Themes to Watch for in 2025
- Transportation Stocks Investing
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- What Are Dividend Challengers?
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.